Breaking News Instant updates and real-time market news.

BMRN

BioMarin

$94.44

0.43 (0.46%)

, PRQR

ProQR Therapeutics

$15.46

0.55 (3.69%)

07:30
01/14/19
01/14
07:30
01/14/19
07:30

Cantor highlights BioMarin, ProQR after JPMorgan Healthcare Conference

Cantor Fitzgerald analyst Eliana Merle found BioMarin's (BMRN) gene therapy platform advances and "improved risk-reward" for ProQR Therapeutics' (PRQR) USH2A program ahead of key data mid-2019 as most notable from the JPMorgan Healthcare Conference. The analyst left feeling more confident about BioMarin's gene therapy platform, which she thinks could positively surprise over the next 12-24 months as new programs enter the clinic. Further, she thinks the safety events in question at this point are likely overdone in ProQR shares following the 15% selloff since the conference. Merle now sees an "even more" favorable risk/reward into the company's mid-2019 proof-of-concept readout from a separate program.

BMRN

BioMarin

$94.44

0.43 (0.46%)

PRQR

ProQR Therapeutics

$15.46

0.55 (3.69%)

  • 29

    Jan

BMRN BioMarin
$94.44

0.43 (0.46%)

01/02/19
RAJA
01/02/19
DOWNGRADE
RAJA
Market Perform
BioMarin downgraded to Market Perform on lack of catalysts at Raymond James
As previously reported, Raymond James downgraded BioMarin to Market Perform from Outperform Analyst Laura Chico said BioMarin lacks near-term catalysts which makes it more vulnerable in a "risk off" environment. The analyst notes key valorx events do not manifest until mid-2019, and vosoritde later in the year.
01/02/19
01/02/19
DOWNGRADE

Fly Intel: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Henry Schein (HSIC) downgraded to Neutral from Outperform at Baird with analyst Jeff Johnson saying he is more cautious on the combination of the dental sector's secular overhangs, softer Q4 patient volume checks, and accelerating equipment pricing pressures. 2. Conagra Brands (CAG) downgraded to Buy from Conviction Buy at Goldman Sachs with analyst Jason English saying while the stock's 41% decline since October 23 is overdone, the "path of recovery is likely to be protracted." 3. BioMarin (BMRN) downgraded to Market Perform from Outperform at Raymond James with analyst Laura Chico saying BioMarin lacks near-term catalysts which makes it more vulnerable in a "risk off" environment. 4. Hologic (HOLX) downgraded to Underweight from Equal Weight at Morgan Stanley with analyst David Lewis saying his checks with about 40 medspas highlighted market saturation of body sculpting devices. 5. Louisiana-Pacific (LPX) downgraded to Neutral from Buy at BofA/Merrill with analyst George Staphos citing the steep drop-off in 2H 2018 panel pricing and challenging 1H 2019 comparisons versus 1H 2018. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
01/03/19
PIPR
01/03/19
NO CHANGE
PIPR
Piper sees Alexion, Biogen as potential targets after Celgene buyout
Piper Jaffray analyst Christopher Raymond remains "bullish on biotech" in the wake the announced acquisition of Celgene (CELG) by Bristol-Myers Squibb (BMY) for $74B in cash and stock, representing a 54% premium from yesterday's close. In a research note titled "Bristol for CELG - In Retrospect, it Makes Perfect Sense," Raymond says the market is likely to ask "who's next?" Among large-caps, Alexion Pharmaceuticals (ALXN) and Biogen (BIIB) would seem to make sense as potential targets, as well as BioMarin (BMRN), Raymond writes. And while any smid cap could likely be seen as a take-out candidate, Aimmune Therapeutics (AIMT), Deciphera Pharmaceuticals (DCPH) and Rigel Pharmaceuticals (RIGL) "in particular could make sense to any strategic buyer," adds the analyst.
01/10/19
JEFF
01/10/19
NO CHANGE
Target $125
JEFF
Buy
BioMarin shares well positioned for upside, says Jefferies
After meeting with management, Jefferies analyst Eun Yang keeps a Buy rating on BioMarin with a $125 price target. With multiple clinical/regulatory catalysts in 2019, BioMarin is well positioned for upside, Yang tells investors in a research note. She believes the third-year durability data for valox in mid-2019 could potentially move the shares 20%.
PRQR ProQR Therapeutics
$15.46

0.55 (3.69%)

11/14/18
CANT
11/14/18
INITIATION
Target $40
CANT
Overweight
Cantor starts ProQR with Overweight despite 500% year-to-date rally
Cantor Fitzgerald analyst Eliana Merle last night initiated coverage of ProQR Therapeutics with an Overweight rating and $40 price target. ProQR is a European RNA-based platform technology company focused on developing therapeutics for inherited blindness, Merle tells investors in a research note. Although shares are up close to 500% year-to-date after positive proof of concept in first ophthalmology drug QR-110, "this could be just the beginning of a major turning point for the company's platform," says the analyst. He thinks QR-110 "could be just the tip of the iceberg" in terms of ProQR's platform potential in inherited forms of blindness. Merle believes its clinical program in Usher's syndrome represents a larger opportunity than QR-110.
11/14/18
11/14/18
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Avid (AVID) initiated with a Hold at Jefferies. 2. ProQR Therapeutics (PRQR) initiated with an Overweight at Cantor Fitzgerald. 3. GW Pharmaceuticals (GWPH) initiated with an Outperform at Leerink. 4. Equitrans Midstream (ETRN) initiated with an Overweight at US Capital Advisors. 5. Zymogenetics (ZGEN) and Allergan (AGN) were initiated with an Outperform at Leerink. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
11/15/18
SBSH
11/15/18
INITIATION
Target $32
SBSH
Buy
ProQR Therapeutics initiated with a Buy at Citi
Citi analyst Yigal Nochomovitz started ProQR Therapeutics (PRQR) with a Buy rating and $32 price target. The company's lead program for Leber congenital amaurosis 10, a severe eye disease leading to childhood blindness, has achieved proof-of-concept, Nochomovitz tells investors in a research note. The data reflect a degree of visual benefit "arguably better" than what Spark Therapeutics' (ONCE) Luxturna showed in the related disease LCA2, says the analyst.
12/19/18
RBCM
12/19/18
INITIATION
Target $29
RBCM
Outperform
ProQR Therapeutics initiated with an Outperform at RBC Capital
RBC Capital analyst Kennen MacKay initiated ProQR Therapeutics with an Outperform rating and a price $29. The analyst believes that the company's recent QR-110 data serves to de-risk its ophthalmology portfolio, offering "upside potential from pipeline expansion in 2019" and beyond. MacKay is also positive on ProQR Therapeutics position of having an "established proof of concept utilizing RNA-based therapies to target rare diseases uniquely sheltered from safety and efficacy challenges" faced by its therapeutic class.

TODAY'S FREE FLY STORIES

02:50
01/22/19
01/22
02:50
01/22/19
02:50
General news
FX Update: The Dollar and Yen have traded firmer »

FX Update: The Dollar…

WOLWF

Woolworths Group

$0.00

(0.00%)

18:51
01/21/19
01/21
18:51
01/21/19
18:51
Downgrade
Woolworths Group rating change at Citi »

Woolworths Group…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LLESY

Lendlease Group

$0.00

(0.00%)

18:48
01/21/19
01/21
18:48
01/21/19
18:48
Upgrade
Lendlease Group rating change at Citi »

Lendlease Group upgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EFSC

Enterprise Financial

$41.41

0.99 (2.45%)

17:56
01/21/19
01/21
17:56
01/21/19
17:56
Earnings
Enterprise Financial reports Q4 EPS $1.02, consensus 95c »

Reports Q4 core revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jan

FB

Facebook

$150.01

1.77 (1.19%)

16:36
01/21/19
01/21
16:36
01/21/19
16:36
Periodicals
Facebook planning to add 1,000 jobs in Ireland by year-end, Reuters says »

Facebook will hire an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jan

  • 24

    Jan

  • 30

    Jan

  • 25

    Feb

  • 03

    Mar

FB

Facebook

$150.01

1.77 (1.19%)

16:33
01/21/19
01/21
16:33
01/21/19
16:33
Periodicals
Facebook's WhatsApp limits users to five text forwards, Reuters reports »

Facebook's WhatsApp…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jan

  • 24

    Jan

  • 30

    Jan

  • 25

    Feb

  • 03

    Mar

ENB

Enbridge

$36.10

0.425 (1.19%)

16:28
01/21/19
01/21
16:28
01/21/19
16:28
Periodicals
Enbridge gas pipeline explosion creates fireball in Ohio, Reuters says »

An explosion of an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LIN

Linde plc

$160.76

3.48 (2.21%)

16:25
01/21/19
01/21
16:25
01/21/19
16:25
Periodicals
Linde Plc to launch $6B share buyback scheme, Reuters says »

Linde Plc said it would…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    May

HENKY

Henkel

$0.00

(0.00%)

16:01
01/21/19
01/21
16:01
01/21/19
16:01
Downgrade
Henkel rating change at Goldman Sachs »

Henkel downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CAG

Conagra Brands

$21.58

0.34 (1.60%)

14:06
01/21/19
01/21
14:06
01/21/19
14:06
Hot Stocks
Conagra exploring alternatives for Italian-based frozen pasta business »

Conagra Brands announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jan

13:15
01/21/19
01/21
13:15
01/21/19
13:15
General news
IMF trimmed global growth amid "no-deal" Brexit and trade war concerns »

IMF trimmed global growth…

UQM

UQM Technologies

$1.10

0.05 (4.76%)

13:05
01/21/19
01/21
13:05
01/21/19
13:05
Hot Stocks
UQM Technologies acquired by Danfoss Power Solutions for $1.71 per share »

UQM Technologies…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SNY

Sanofi

$41.50

-0.54 (-1.28%)

12:37
01/21/19
01/21
12:37
01/21/19
12:37
Hot Stocks
Sanofi granted U.K. marketing authorization for TIV High Dose »

U.K. marketing…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jan

  • 28

    Jan

  • 11

    Mar

  • 22

    Mar

  • 28

    Apr

RTN

Raytheon

$165.11

2.285 (1.40%)

12:33
01/21/19
01/21
12:33
01/21/19
12:33
Hot Stocks
Raytheon awarded $24.36M order for F/A-18 aircraft system repair »

Raytheon said it was a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IBCP

Independent Bank

$22.80

-0.11 (-0.48%)

11:26
01/21/19
01/21
11:26
01/21/19
11:26
Hot Stocks
Independent Bank boosts quarterly dividend by 20% to 18c »

Independent Bank…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Jan

11:25
01/21/19
01/21
11:25
01/21/19
11:25
General news
FX Update: The dollar majors have been directionally challenged »

FX Update: The dollar…

EDIT

Editas Medicine

$26.16

-0.01 (-0.04%)

11:25
01/21/19
01/21
11:25
01/21/19
11:25
Hot Stocks
Editas Medicine announces publication of EDIT-101 data in Nature Medicine »

Editas Medicine announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GOOG

Alphabet

$1,098.25

6.96 (0.64%)

, GOOGL

Alphabet Class A

$1,106.92

7.52 (0.68%)

11:23
01/21/19
01/21
11:23
01/21/19
11:23
Hot Stocks
France's National Data Protection Commission fines Google 50M euros »

France's National…

GOOG

Alphabet

$1,098.25

6.96 (0.64%)

GOOGL

Alphabet Class A

$1,106.92

7.52 (0.68%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jan

  • 24

    Jan

  • 04

    Feb

  • 04

    Feb

  • 25

    Feb

  • 03

    Mar

LAD

Lithia Motors

$87.13

1.57 (1.84%)

10:25
01/21/19
01/21
10:25
01/21/19
10:25
Conference/Events
Lithia Motors to host special shareholder meeting »

Special shareholder…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Jan

  • 13

    Feb

  • 14

    Mar

CYDY

CytoDyn

$0.00

(0.00%)

10:25
01/21/19
01/21
10:25
01/21/19
10:25
Conference/Events
CytoDyn participates in lunch meeting with Philadelphia Securities »

Luncheon Meeting with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Jan

ABT

Abbott

$71.43

0.9 (1.28%)

09:50
01/21/19
01/21
09:50
01/21/19
09:50
Hot Stocks
Abbott announces FDA approval of TactiCath Contact Force Ablation Catheter »

Abbott announced FDA…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 27

    Jan

SFUN

Fang Holdings

$1.88

-0.01 (-0.53%)

09:48
01/21/19
01/21
09:48
01/21/19
09:48
Hot Stocks
Fang announces management changes, proposed China Index spin-off »

Fang Holdings announced a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TS

Tenaris

$24.32

0.64 (2.70%)

09:45
01/21/19
01/21
09:45
01/21/19
09:45
Hot Stocks
Tenaris closes acquisition of 47.79% of Saudi Steel Pipe shares »

Tenaris S.A. announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PAAS

Pan American Silver

$14.17

-0.31 (-2.14%)

09:42
01/21/19
01/21
09:42
01/21/19
09:42
Hot Stocks
Pan American reports 2018 silver production 24.8M ounces »

Pan American Silver Corp.…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CRWS

Crown Crafts

$5.68

(0.00%)

09:38
01/21/19
01/21
09:38
01/21/19
09:38
Hot Stocks
Crown Crafts announces retirement of NoJo Baby & Kids CEO »

Crown Crafts (CRWS)…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.